Formulation and Evaluation of Mefenamic Acid Solid Dispersions Employing Starch Citrate-A New Solubility Enhancer

  • Rada Santosh Kumar GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA
  • Annu Kumari GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA

Abstract

Solid dispersions refer to the group of solid products consisting of at least a hydrophilic carrier and hydrophobic drug. Drug is molecularly dispersed in amorphous form. Solubility and dissolution rate is the rate determining step for bioavailability of mefenamic acid, a BCS class II drug. In this paper, preparation of starch citrate and evaluation of it, as a solubility enhancer by formulating solid dispersion using mefenamic acid will be discussed. For evaluation, as solubility enhancer, of starch citrate in vitro evaluation of solid dispersion (prepared by physical method, solvent evaporation method and kneading method) was done. Starch citrate found to be a novel carrier and solubility enhancer of poorly soluble drugs.


Keywords: Mefenamic acid, Starch citrate, Solid dispersion & In vitro studies, physical method, solvent evaporation, kneading method

Downloads

Download data is not yet available.

Author Biographies

Rada Santosh Kumar, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA

GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA

Annu Kumari, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA

GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, A.P 530045, INDIA

References

1. Vasconcelos T, BSarmento, Costa P, Solid dispersion as strategy to improve oral bioavailablity of poor water soluble drugs. Drug Discovery Today 2007; 12(23-24):1068-1075.
2. Jennifer Dressman CL, Improving drug solubility for oral delivery using solid dispersions, European Journal of Pharmaceutics and Biopharmaceutics, 2000; 50(1):47-60.
3. Dhirendra K.; Lewis S.; Udupa N.; Atin K., Solid dispersions: a review, Pakistan Journal of Pharmaceutical Sciences, 2009, 22(2):234-246.
4. Saharan VA, Kukkar V, Kataria M, Gera M, Choudhury PK, Dissolution Enhancement of Drugs. Part I: Technologies and Effect of Carriers, International Journal of Health Research, June 2009; 2(2):107-124.
5. Nurhikmah W, Sumirtapura YC, Pamudji JS, Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media, Sci Pharm. 2016; 84:181–190.
6. Nagabhushanam MV, Sudha Rani A, Dissolution enhancement of mefenamic acid using solid dispersions in crospovidone, International Journal of Pharmacy and Pharmaceutical Sciences, 2011; 3(1):16-19.
7. Chowdary KPR, Enturi V, Sujatha S, Preparation and evaluation of starch citrate: a new modified starch as directly compressible vehicle in tablet formulations, Int. J. Chem. Sci. 2011; 9(1):177-187.
8. Amaravathi V, Firoz S, Kishore D, Chandra Mouli Y, Venkataramudu T, Formulation and evaluation of mefenamic acid tablets by using modified starch, Asian Journal of Pharmaceutical Science & Technology, 2012; 2(2):46-53.
9. Sambasiva Rao KRS, Nagabhushanam MV, Chowdary KPR, In vitro Dissolution Studies on Solid Dispersions of Mefenamic Acid, Indian J Pharm Sci. 2011; 73(2):243–247.
10. Jamal SS, Saleem S, Pavan Kumar Alaparthi N, Bachupally AK, Punuru M, Formulation and evaluation of mefenamic acid solid dispersions using PEG-4000, International Research Journal of Pharmacy, 2013; 4(5):155-159.
11. Prasada Rao CHV, Nagabhushanam MV, Enhancement of dissolution profile of mefenamic acid by solid dispersion technique, International journal of research in pharmacy and chemistry, 2011; 1(4):1127-1134.
Statistics
46 Views | 60 Downloads
How to Cite
Santosh Kumar, R., & Kumari, A. (2019). Formulation and Evaluation of Mefenamic Acid Solid Dispersions Employing Starch Citrate-A New Solubility Enhancer. Journal of Drug Delivery and Therapeutics, 9(2-s), 48-52. https://doi.org/10.22270/jddt.v9i2-s.2585